Enzolytics Inc (ENZC)

[sspalmo]

In the same document, page 32 states $450 million. "The sales transaction was valued at $450,000,000" It's odd that page 23 states $360 million. "in a stock transaction valued at $360 million" The $90 million difference does line up with what the board members were to receive. It is probably just sloppiness on the part whomever wrote the PR to reference the transaction that occured September 18, 2023 with two different transaction values.

On September 18, 2023, the Company executed and closed a business combination agreement with
Sagaliam Acquisition Corp, selling 100% of the Company’s ownership in the two operating subsidiaries,
Virogentics, Inc. (“VIRO”) and Biogenysis, Inc. (“BGEN”). Prior to September 18, 2023, Enzolytics was a
biotechnology company, whose products consisted of multiple distinct drug development proprietary
technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies and an artificial
intelligence (AI) platform for health care developments. The Company had clinically tested anti-HIV
therapeutics. Additionally, the Company had created a proprietary cell line that produces fully human
monoclonal antibodies that target and neutralizes the HIV virus. The sales transaction was valued at
$450,000,000 to the shareholders of the operating subsidiaries of the Company with a Make-whole
provision

https://www.otcmarkets.com/otcapi/company/financial-report/403184/content